GlassScriptPhysician profile
Bradley H Kessler
NPI 1700887551
$5,587.94
in general payments reported to CMS, 2019-2025
44 companies · $1,838 in 2025
The $1,838 reported for 2025 was more than what 86% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $182 · 2021: $424 · 2022: $519 · 2023: $1,384 · 2024: $847 · 2025: $1,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,069.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,574.22 | 2019-2025 | |
| Genzyme Corporation | $820.86 | 2021-2025 | |
| Mirum Pharmaceuticals, INC. | $447.69 | 2023-2025 | Livmarli, Cholbam |
| Supernus Pharmaceuticals, INC. | $249.98 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $172.01 | 2022-2025 | Azstarys |
| Janssen Biotech, INC. | $169.40 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $167.04 | 2022-2024 | Dupixent |
| Pfizer INC. | $158.71 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $147.45 | 2021-2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $142.58 | 2020-2025 | Eohilia |
| Neurelis, INC. | $128.01 | 2020-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $118.79 | 2022-2024 | Strensiq, Ultomiris |
| Glaxosmithkline, LLC. | $94.58 | 2021-2024 | Nucala |
| Qol Medical, LLC | $87.51 | 2025 | Sucraid |
| Acadia Pharmaceuticals INC | $87.31 | 2023-2025 | Daybue |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $79.79 | 2023-2024 | Jornay Pm |
| Ucb, INC. | $71.27 | 2022-2025 | Briviact |
| Ipsen Biopharmaceuticals, INC | $66.18 | 2023-2025 | Bylvay |
| Global Blood Therapeutics, INC. | $59.61 | 2020-2022 | |
| Amphastar Pharmaceuticals, INC. | $59.29 | 2024-2025 | |
| Medtronic, INC. | $59.26 | 2024 | Minimed 780g |
| Endo USA, INC. | $50.67 | 2025 | Supprelin |
| Ironwood Pharmaceuticals, INC | $48.50 | 2024 | |
| Tris Pharma INC | $40.70 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $40.56 | 2024-2025 | Zonisade, Triptodur |
| Ascendis Pharma Endocrinology INC | $40.49 | 2025 | Skytrofa |
| Novo Nordisk INC | $38.93 | 2024-2025 | Sogroya, Rivfloza |
| Biomarin Pharmaceutical INC. | $36.98 | 2023 | Brineura, Voxzogo 1.2mg |
| Tolmar, INC. | $33.38 | 2025 | Fensolvi |
| Sobi, INC | $31.25 | 2023 | |
| Electromed, INC. | $28.56 | 2025 | Smartvest |
| Philips North America LLC | $23.20 | 2025 | Vest Therapy Und |
| Catalyst Pharmaceuticals, INC. | $22.44 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.39 | 2020 | |
| Zogenix INC. | $22.01 | 2021 | |
| Amneal Pharmaceuticals LLC | $20.96 | 2025 | Unithroid |
| Neos Therapeutics, LP | $18.94 | 2023 | Adzenys Xr-Odt |
| Phadia US INC. | $18.23 | 2023 | Immunocap |
| Tandem Diabetes Care, INC. | $15.90 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ferring Pharmaceuticals INC. | $15.73 | 2020 | |
| Jazz Pharmaceuticals INC. | $15.37 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.51 | 2021 | |
| Greenwich Biosciences, INC. | $13.96 | 2021 | |
| Cognoa, INC. | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.